Company: Open Orphan (ORPH)
Presenter: Cathal Friel, Executive Chairman
Date: Monday 11th May 2020
Time: 5pm start - 6pm finish
Company Information: Open Orphan is a newly created niche CRO pharmaceutical services company which is the world leader in testing vaccines & antivirals through human challenge studies. Open Orphan is actively involved in the fight against COVID-19 and is developing the world’s first coronavirus challenge study model. In June 2019 Open Orphan acquired AIM-listed Venn Life Sciences plc in a reverse take-over and in January 2020 completed a merger with hVIVO plc. hVIVO has Europe's only 24-bedroom quarantine clinic with onsite virology lab and has recently commenced testing on a potential antiviral treatment for COVID-19 Open Orphan (ORPH) is quoted on both the AIM and Euronext Growth market
Registration is open to members of ShareSoc. Click here to register for this webinar.